Healthy Volunteers Clinical Trial
Official title:
Metabolic and Neural Adaptations to Weight Loss, Plateau, and Regain
Verified date | June 29, 2017 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- Many people can lose weight by changing their diet or exercise. However, most people
eventually regain the weight over time. This weight regain may be related to changes in
metabolism as well as changes in the brain caused by weight loss. Researchers want to learn
more about these changes.
Objective:
- To see how weight loss and regain affects the body s metabolism and the brain of obese but
healthy adults.
Eligibility:
- Obese but healthy adults age 18-55 who plan to participate in a weight loss program at one
of several participating clinics or resorts.
Design:
- Participants will first be screened at home through questionnaires and telephone
interviews.
- Participants will then be screened at the NIH with blood tests, medical history,
physical exam, electrocardiograms, and questionnaires. They will have a mock magnetic
resonance imaging (MRI) scan.
- At visit 1, participants will stay at the NIH and will:
- have MRI and PET brain scans.
- have body composition scans and measurements.
- give blood samples.
- eat a special diet.
- wear a physical activity monitor.
- provide a urine sample and body weight daily.
- drink a special type of water to measure calorie burn.
- wear a clear plastic hood over their head while lying down, to collect exhaled air.
- spend 24 hours in a room that measures oxygen and carbon dioxide.
- complete questionnaires and computer tasks.
- After visit 1, participants will give daily urine samples and weight and physical
activity measurements from home. Then they will follow a lifestyle intervention for
weight loss and give daily weight and activity measurements.
- Visits 2, 3, and 4 occur 1-26 months after the start of the weight loss program.
Participants will repeat procedures from visit 1. Visits 1-4 last 4 days each.
- Researchers will track participants weight and physical activity for up to 26 months
after visit 2.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | June 29, 2017 |
Est. primary completion date | June 29, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
- INCLUSION CRITERIA: - Age 18-55 years, male and female - Recent weight stability (< plus and minus 2 % over past 1 month) - Body mass index (BMI) greater than or equal to 30 kg/m2 - Able to complete daily bouts of moderate to vigorous exercise (when applicable) - Written informed consent - Have reserved a stay of at least 4 weeks at The Biggest Loser Resort or have enrolled in a structured meal replacement weight loss program at the Washington Center for Weight Management and Research, the National Center for Weight and Wellness, or the Johns Hopkins Weight Management Center. EXCLUSION CRITERIA: - Body weight > 400 lbs (weight limit of PET and MRI scanners) - BMI < 30 kg/m2 - Less than 80% of maximum lifetime weight - Hypertension if - (1) >160/100; - (2) 140/90 to 159/99 with evidence of target organ damage (e.g. elevated serum creatinine, proteinuria, abnormal EKG, retinopathy); - (3) >140/90 on antihypertensive medications. - Evidence of metabolic or cardiovascular disease, or disease that may influence metabolism (e.g. cancer, thyroid disease) - Past or present history of eating disorder (including binge eating) or psychiatric disease - Taking any prescription medication or other drug that may influence metabolism (e.g. diet/weight-loss medication, asthma medication, psychiatric medications, corticosteroids, or other medications at the discretion of the PI and/or study team) - Hematocrit < 34% (women only) - Hematocrit < 40% (men only) - Pregnancy, lactation (women only) - Women who become pregnant during the two-year study period - Recent participation in a regular exercise program (> 4h/week of vigorous activity) - Previous bariatric surgery - Caffeine consumption > 500 mg/day - Regular use of alcohol (>2 drinks per day), tobacco (smoking or chewing) amphetamines, cocaine, heroin, or marijuana over past 6 months - Volunteers with strict dietary concerns (e.g. vegetarian or kosher diet, multiple food allergies) - Having metal implants incompatible with MRI (for example, pacemakers, metallic prostheses such as cochlear implants or heart valves, shrapnel fragments, etc.). - Non-native English speakers - Volunteers unwilling or unable to give informed consent |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Arone LJ, Mackintosh R, Rosenbaum M, Leibel RL, Hirsch J. Autonomic nervous system activity in weight gain and weight loss. Am J Physiol. 1995 Jul;269(1 Pt 2):R222-5. — View Citation
Franz MJ, VanWormer JJ, Crain AL, Boucher JL, Histon T, Caplan W, Bowman JD, Pronk NP. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007 Oct;107(10):1755-67. Review. — View Citation
Johannsen DL, Knuth ND, Huizenga R, Rood JC, Ravussin E, Hall KD. Metabolic slowing with massive weight loss despite preservation of fat-free mass. J Clin Endocrinol Metab. 2012 Jul;97(7):2489-96. doi: 10.1210/jc.2012-1444. Epub 2012 Apr 24. Erratum in: J Clin Endocrinol Metab. 2016 May;101(5):2266. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To measure metabolic and neural adaptations after 4-12 weeks, 6-10 months, and 22-26 months following the start of a lifestyle intervention resulting in weight loss. | ongoing | ||
Secondary | To determine whether the degree of metabolic or neural adaptation at 4-12 weeks is correlated with the weight plateau at 6-10 months or the rate of weight regain in the subsequent months. | ongoing | ||
Secondary | To investigate changes in circulating hormone and metabolites that correlate with metabolic and neural adaptations as well as changes in appetitive behaviors following a lifestyle intervention resulting in weight loss. | ongoing |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |